64 filings
EFFECT
ACRV
Acrivon Therapeutics Inc
30 Apr 24
Notice of effectiveness
12:15am
ARS
2023 FY
ACRV
Acrivon Therapeutics Inc
26 Apr 24
Annual report to shareholders
8:36am
DEFA14A
ACRV
Acrivon Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
8:33am
DEF 14A
ACRV
Acrivon Therapeutics Inc
Definitive proxy
26 Apr 24
8:30am
8-K
ACRV
Acrivon Therapeutics Inc
24 Apr 24
Results of Operations and Financial Condition
4:01pm
8-K
ii78vlx1uda6iy0afk
9 Apr 24
Acrivon Therapeutics Announces $130 Million Private Placement Financing
7:05am
S-8
zb7ah
29 Mar 24
Registration of securities for employees
9:06am
8-K
0u5337v42fn u2ox1
28 Mar 24
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
8:00am
8-K
ofug5 4wkd1
4 Mar 24
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
8:15am
8-K
r88uhf0
8 Feb 24
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
8:27am
8-K
ugl2upm
8 Jan 24
Regulation FD Disclosure
7:28am
EFFECT
61o02wqe 60h
18 Dec 23
Notice of effectiveness
12:15am
CORRESP
c3vg6s375n8q
12 Dec 23
Correspondence with SEC
12:00am
8-K
asrxi
8 Dec 23
Entry into a Material Definitive Agreement
4:21pm
UPLOAD
2vpu wygh
5 Dec 23
Letter from SEC
12:00am
S-3
tgw69ju
1 Dec 23
Shelf registration
4:35pm
8-K
dufowq3u
9 Nov 23
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
9:12am